Gish claims "gold standard" in oxygenators:
This article was originally published in Clinica
Gish Biomedical is launching the Vision hollow fibre oxygenator system worldwide. Gish claims that the product uses state-of-the art design and is more effective in situations of high flow rates, low blood volume and substandard physiology associated with multiple system disorders. The company says that the product could become the gold standard for such devices. Gish plans to distribute the Vision in the US itself and use its network of sales distributors.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.